Literature DB >> 26243652

An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database.

Monika Brand1, Rebecca Hollaender2, Daniel Rosenberg1, Martin Scott3, Elke Hunsche1, Alan Tyndall2, Valentina Denaro4, Patricia Carreira5, Cecilia Varju6, Barbara Gabrielli7, Stefania Zingarelli8, Paola Caramaschi9, Katarina Simic-Pasalic10, Ulf Müller-Ladner11, Massimiliano Vasile12, Carina Mihai13, Edoardo Rosato14, Alessandra Vacca15, Thierry Zenone16, Walid A Mohamed17, Codrina Ancuta18, Giuseppe Zampogna19, Simona Rednic20, Nadia Jabaar21, Laura Belloli22, Maria R Pozzi23, Rosario Foti24, Ulrich A Walker25.   

Abstract

OBJECTIVES: This study describes clinical characteristics, prognostic factors, and quality of life in patients with newly diagnosed (incident) digital ulcers (DU).
METHODS: Observational cohort study of 189 consecutive SSc patients with incident DU diagnosis identified from the EUSTAR database (22 centres in 10 countries). Data were collected from medical charts and during one prospective visit between 01/2004 and 09/2010.
RESULTS: Median age at DU diagnosis was 51 years, majority of patients were female (88%), and limited cutaneous SSc was the most common subtype (61%). At incident DU diagnosis, 41% of patients had one DU and 59% had ≥2 DU; at the prospective visit 52% had DU. Pulmonary arterial hypertension (PAH) and multiple DU at diagnosis were associated with presence of any DU at the prospective visit (odds ratios: 4.34 and 1.32). During the observation period (median follow-up was 2 years) 127 patients had ≥1 hospitalisation. The event rate of new DU per person-year was 0.66, of DU-associated complications was 0.10, and of surgical or diagnostic procedures was 0.12. At the prospective visit, patients with ≥1 DU reported impairment in daily activities by 57%, those with 0 DU by 37%. The mean difference between patients with or without DU in the SF-36 physical component was 2.2, and in the mental component 1.4. DU patients were not routinely prescribed endothelin receptor antagonists or prostanoids.
CONCLUSIONS: This real world cohort demonstrates that DU require hospital admission, and impair daily activity. PAH and multiple DU at diagnosis were associated with future occurrence of DU.

Entities:  

Mesh:

Year:  2015        PMID: 26243652

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  17 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].

Authors:  G Riemekasten; S Beissert; J H W Distler; A Kreuter; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

3.  Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival.

Authors:  Kathleen Morrisroe; Dylan Hansen; Wendy Stevens; Joanne Sahhar; Gene-Siew Ngian; Catherine Hill; Janet Roddy; Jennifer Walker; Susanna Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2022-05-10       Impact factor: 5.606

4.  Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.

Authors:  Jan-Gerd Rademacher; Chris Wincup; Björn Tampe; Peter Korsten
Journal:  J Scleroderma Relat Disord       Date:  2019-09-19

Review 5.  Raynaud phenomenon and digital ulcers in systemic sclerosis.

Authors:  Michael Hughes; Yannick Allanore; Lorinda Chung; John D Pauling; Christopher P Denton; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2020-02-25       Impact factor: 20.543

6.  The critical need for accurately defining digital ulcers in scleroderma.

Authors:  Wendy Li; Tracy M Frech
Journal:  J Scleroderma Relat Disord       Date:  2017-05-19

7.  CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis.

Authors:  Marcella Visentini; Chiara Pellicano; Giorgia Leodori; Ramona Marrapodi; Stefania Colantuono; Antonietta Gigante; Milvia Casato; Edoardo Rosato
Journal:  Clin Exp Immunol       Date:  2021-06-06       Impact factor: 4.330

8.  Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports.

Authors:  Nicola Ughi; Chiara Crotti; Francesca Ingegnoli
Journal:  Clin Interv Aging       Date:  2016-03-14       Impact factor: 4.458

9.  Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry.

Authors:  Marco Matucci-Cerinic; Thomas Krieg; Loic Guillevin; Barbara Schwierin; Daniel Rosenberg; Peter Cornelisse; Christopher P Denton
Journal:  Ann Rheum Dis       Date:  2015-11-26       Impact factor: 19.103

10.  Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study.

Authors:  Maurizio Cutolo; Ariane L Herrick; Oliver Distler; Mike O Becker; Emma Beltran; Patrick Carpentier; Clodoveo Ferri; Murat Inanç; Panayiotis Vlachoyiannopoulos; Harbajan Chadha-Boreham; Emmanuelle Cottreel; Thomas Pfister; Daniel Rosenberg; Juan V Torres; Vanessa Smith
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.